CMIC Holdings Co. Ltd. | Income Statement

Fiscal year is October-September. All values JPY Millions.
2013
2014
2015
2016
2017
2018
Sales/Revenue
50,934
52,836
55,904
62,039
65,282
69,869
Cost of Goods Sold (COGS) incl. D&A
38,749
41,943
44,816
48,941
51,044
54,976
Gross Income
12,185
10,893
11,088
13,098
14,238
14,893
SG&A Expense
8,029
8,127
9,677
9,733
10,340
10,570
EBIT
4,156
2,766
1,411
3,365
3,898
4,337
Unusual Expense
142
69
547
343
310
51
Non Operating Income/Expense
22
82
839
201
65
40
Interest Expense
135
134
144
143
121
116
Pretax Income
3,928
2,467
1,280
2,599
3,269
3,949
Income Tax
2,243
1,268
1,797
1,577
1,596
2,187
Consolidated Net Income
1,685
1,199
517
1,022
1,672
1,761
Net Income
1,753
1,174
542
879
1,551
1,487
Net Income After Extraordinaries
1,753
1,174
542
879
1,551
1,487
Net Income Available to Common
1,753
1,174
542
878
1,550
1,487
EPS (Basic)
97.36
65.23
29.54
46.95
82.87
79.68
Basic Shares Outstanding
18
18
18
19
19
19
EPS (Diluted)
97.31
65.23
29.54
46.95
82.87
79.68
Diluted Shares Outstanding
18
18
18
19
19
19
EBITDA
6,423
4,793
4,308
6,485
7,075
7,782
Non-Operating Interest Income
10
9
12
31
16
6
Minority Interest Expense
68
25
25
143
121
274
Equity in Affiliates (Pretax)
61
23
291
108
147
182

About CMIC Holdings Co.

View Profile
Address
Hamamatsucho Building
Tokyo Tokyo 105
Japan
Employees -
Website http://www.cmic-holdings.co.jp
Updated 07/08/2019
CMIC Holdings Co., Ltd. engages in the provision of support services for pharmaceutical development, manufacturing, and sales. Its operations are carried out through the following segments: Contract Research Organization (CRO), Contract Manufacturing Organization (CMO), Contract Sales Organization (CSO), Health Care, and Intellectual Properties Development (IPD). The CRO segment provides the professional services related to the administration of clinical study and survey upon manufacture and sale such as monitoring, data management, pharmaceutical consulting, and preclinical businesses.